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Outside In or Inside Out?*
David J. Wilber, MD
Maywood, IllinoisPercutaneous epicardial access, introduced by Sosa et al. (1)
in the mid-1990s, provided an important diagnostic and
therapeutic approach to the recognition and management of
scar-related epicardial ventricular tachycardia (VT). Since
that time, the need for epicardial ablation has been reported
in 10% to 15% of patients with ischemic cardiomyopathy
(ICM) (2–4), 25% to 50% of patients with nonischemic
cardiomyopathy (NICM) (4–8), and 30% to 40% of patients
with arrhythmogenic right ventricular cardiomyopathy
(ARVC) (4,9–12). Controversy persists with regard to the
timing of epicardial intervention (initial procedure or only
after unsuccessful endocardial approaches) and the extent of
epicardial ablation required (focused regional ablation tar-
geting speciﬁc VT morphologies or elimination of all
epicardial late or abnormal potentials [13,14]). These con-See page 1416troversies persist for several reasons. Percutaneous epicardial
interventions are associated with a 4% to 7% risk of major
complications (4,15), including subdiaphragmatic or intra-
pericardial bleeding, coronary artery injury, and phrenic nerve
damage. Percutaneous epicardial access can be technically
challenging, particularly in patients with prior cardiac surgery
or pericarditis. Finally, the presence of fat more than a few
millimeters thick reduces the depth and volume of ablation
lesions, thereby reducing the effectiveness of epicardial
ablation (16).*Editorials published in the Journal of the American College of Cardiology reﬂect the
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this paper to disclose.The study of Komatsu et al. (17), published in this issue
of the Journal, provides important new information and
sheds additional light on these issues. The goal of the study
was to determine the impact of endocardial ablation alone
on the epicardial substrate for VT. In 51 patients with scar-
related VT, high-density endocardial and epicardial map-
ping was performed with a 3-dimensional navigation system.
In 46 patients, epicardial local abnormal ventricular activities
(LAVA) were identiﬁed and comprised the subjects for this
report (18 ICM, 13 NICM, 15 ARVC). Only a minority of
patients (9%) had undergone a previous ablation procedure.
Radiofrequency (RF) ablation was performed with an open
irrigated catheter. The primary endpoint was elimination of
all LAVA. By study design, the authors attempted to
eliminate all epicardial LAVA by endocardial ablation ﬁrst,
with monitoring of the overlying epicardial surface by a
multielectrode array.
The most important ﬁnding of the study was the relative
effectiveness of endocardial ablation in eliminating epicardial
LAVA and terminating epicardial VT. At 173 sites, endo-
cardial ablation of epicardial LAVA was attempted (46%
of sites had coexisting endocardial LAVA). Elimination of
the appositional epicardial LAVA was achieved in 28%.
Elimination of epicardial LAVA was more likely at endo-
cardial sites with lower bipolar and unipolar voltage and
where endocardial LAVA were also present. The type of
underlying structural heart disease played an important role;
successful endocardial ablation of epicardial LAVA occurred
at 40% of sites in patients with ARVC, 28% with ICM,
and 8% with NICM. From a global perspective, complete
elimination of epicardial LAVA by endocardial ablation
alone occurred in 13% of patients with ARVC, 22% with
ICM, and none with NICM. At least partial elimination
of epicardial LAVA occurred in 73% of patients with
ARVC, 83% with ICM, and 13% with NICM. The
outcome of conventional activation and entrainment map-
ping during stable VT revealed a similar pattern. In 23 of 39
mapped VTs, the critical isthmus was found to be on the
epicardium. Of these epicardial VTs, 5 (22%) terminated
during initial endocardial ablation (33% ARVC, 28% ICM,
and 0 NICM).
The authors provide further insight into the potential
mechanism for successful endocardial ablation of the
epicardial substrate by examining data from multi-detector
computed tomography scans obtained pre-procedurally in
21 patients (12 ICM, 9 IDCM). The scans were subse-
quently extracted and integrated into the electroanatomical
map after the procedure. A region of wall thinning (<5 mm
thickness) was present in all patients except 1 with NICM.
Endocardial ablation was successful in eliminating epicardial
LAVA at 32% of sites associated with wall thinning but at
none of the sites without thinning. Of importance, epicar-
dial LAVA were more commonly found at sites with wall
thinning in ICM (88%) compared with NICM (46%). In
the absence of CT data, the strongest predictor of patient
response to endocardial ablation was the presence of all
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voltage zone. The less frequent association of epicardial
substrate with wall thinning in patients with NICM might
help account for the very poor response of NICM compared
with ICM to endocardial ablation alone. Together with
other indirect evidence (larger endocardial and epicardial
scar areas), the study indicates that endocardial ablation of
epicardial substrate (LAVA, critical isthmuses) is most likely
to occur in areas of large, thinned transmural scars.
Production of transmural lesions in normal ventricular
myocardium by endocardial ablation, even with irrigated RF,
is rare (18). Thus, it is not surprising that scar-associated wall
thinning enhances the probability that subepicardial and
intramural arrhythmogenic substrate will be incorporated
into lesion. In this study, RF energy was applied at a median
power of 35W for a median duration of approximately 1 min.
However, lesion depth and volume are greater with higher
powers or longer durations than those employed in this study,
although the risk of steam pops and thrombus formation
also increases (18,19). Nonetheless, it is possible that higher
power or longer duration applications might have further
increased the effectiveness of endocardial RF at selected sites.
Endocardial ablation might also eliminate epicardial LAVA
without transmural lesions when the isolated epicardial ﬁbers
producing LAVA are predominantly activated transmurally
rather than from the surrounding subepicardium.
How do we best incorporate the lessons from this study
into our current practice of scar-related VT ablation? In
patients where concomitant endocardial and epicardial
mapping is undertaken, the message is clear. Initial endo-
cardial ablation might eliminate some epicardial LAVA and
critical VT circuit sites, reducing the extent and in some
cases the necessity of epicardial ablation. This approach
might be particularly useful where effective epicardial abla-
tion is limited by the proximity to major coronary arteries,
the phrenic nerve, or thick layers of epicardial fat. In the
absence of integrated pre-procedural images at the time of
ablation, sites where endocardial ablation is most effective
can be predicted by low unipolar voltage and the presence of
endocardial LAVA.
From a broader perspective, data from this study help to
reconcile several disparate clinical observations with regard to
epicardial VT ablation. Despite reports that epicardial
LAVA are common in patients with ICM when they are
speciﬁcally looked for (up to 90% [13,20]), the proportion of
patients that require epicardial ablation for long-term clinical
success seems considerably lower. Although the arrhythmo-
genic substrate in ICM is more extensive subendocardially
(20), elimination of the overlying epicardial substrate
by endocardial ablation through thinned scar might also
contribute to the less frequent need for epicardial ablation in
this population. These observations, in conjunction with the
challenges of epicardial access associated with prior surgical
revascularization in a substantial proportion of these patients,
provide a rationale for deferring epicardial intervention in
patients with ICM to those with clinical recurrence of VTafter technically adequate initial endocardial ablation. By
contrast, the arrhythmogenic substrate of NICM is more
commonly subepicardial or intramural, often with little
extension to the subendocardium (5,7,8,20). Furthermore,
as Komatsu et al. (17) demonstrate, the extent of thinned
transmural scar is considerably less in this population.
Endocardial ablation targeting epicardial substrate (LAVA
and/or critical isthmuses) was almost uniformly ineffective.
These data indicate that a more aggressive strategy for
initial epicardial access and intervention in NICM remains
clinically appropriate.
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